前臨床CROの世界市場2014-2025:サービスタイプ別(生物分析・DMPK試験、毒性試験、その他の前臨床サービス)、最終用途別

◆英語タイトル:Preclinical CRO Market Analysis By Service Type (Bioanalysis & DMPK Studies, Toxicology Testing, Other Preclinical Services), By End-use, And Segment Forecasts, 2014 - 2025
◆商品コード:GVIEW801134
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2017年11月15日
◆ページ数:94
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:化学
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi UserUSD5,950 ⇒換算¥654,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,094,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、前臨床CROの世界市場について調査・分析し、前臨床CROの世界市場動向、前臨床CROの世界市場規模、市場予測、セグメント別前臨床CRO市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global preclinical CRO market is anticipated to reach USD 6.6 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness lucrative growth during the forecast period owing to rise in R&D expenditure on early stage development as well as increase in number of drugs in preclinical phase. Hence, increase in outsourcing penetration is further expected to contribute to the growing demand of life science companies for outsourced preclinical services.
Rise in the number of complex drugs entering preclinical trial and growing pressure to curb R&D expenses are expected to contribute to the growing demand for quality CROs, thereby contributing to the market growth. As per Servier Research Institute, issues related to nonclinical toxicology testing results in a 50.0% failure rate in the early stage development phase. High failure rate in this phase is expected to contribute to the demand for early stage development CROs during the forecast period.

Rise in outsourcing of R&D and growing competency of CROs are expected to further contribute to the growing demand for early stage development CROs by life science companies. CRO’s such as Charles River Laboratories and LabCorp specialize in early phase development services. Vendors in emerging countries, such as India and China, provide quick preclinical services at lower costs, which contributes to the outsourcing of R&D.

Further Key Findings From the Study Suggest:

• Toxicology testing held the largest share in the service segment as of 2016 and is expected to dominate over the forecast period. The attrition of drugs due to toxicity is fueling demand for outsourcing of preclinical studies to CROs, which offer end-to-end services, including toxicology testing.

• Biopharmaceutical companies are the major clients for preclinical vendors and held the highest share in the end-use segment in 2016 and is expected to dominate over the forecast period.

• North America is expected to dominate preclinical CRO market over the forecast period owing to local presence of established early development CRO’s, such as Charles River Laboratories International, Inc.; Laboratory Corporation of America; and Envigo. In addition, better quality of work, established scientific experience, economic stability, and better logistics are other major factors for dominance of the region in the global preclinical trial outsourcing market.

• Some of the key players in the preclinical CRO market are Charles River Laboratories International, Inc.; Laboratory Corporation of America; Envigo; Eurofins Scientific; PRA Health Science, Inc.; Wuxi AppTec; Medpace, Inc.; Pharmaceutical Product Development, LLC; and Paraxel International Corporation

【レポートの目次】

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
Chapter 2. Methodology and Scope
2.1. Information Procurement
2.1.1. Purchased database
2.1.2. GVR’s internal database
2.2. Data Analysis
2.3. Market Formulation & Validation
2.4. Approaches for Market Estimation
2.4.1. Approach 1: Commodity flow & bottom-up approach
2.4.2. Approach 2: Top-down and parent market analysis
Chapter 3. Preclinical CRO Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Driver Analysis
3.3. Penetration & Growth Prospect Mapping
3.4. SWOT Analysis, by Factor
3.4.1. Political
3.4.2. Economic
3.4.3. Technological
3.5. Industry Analysis – Porter’s
Chapter 4. Preclinical CRO: Service Estimates & Trend Analysis
4.1. Preclinical CRO Market Share, 2016 & 2025
4.2. Market Size, Estimates & Forecasts, and Trend Analyses, 2014 to 2025 for the following products:
4.2.1. Bioanalysis and DMPK studies
4.2.1.1. Bioanalysis and DMPK studies market estimates and forecasts, 2014 to 2025
4.2.2. Toxicology testing
4.2.2.1. Toxicology testing market estimates and forecasts, 2014 to 2025
4.2.3. Other Preclinical services
4.2.3.1. Other preclinical service market estimates and forecasts, 2014 to 2025
Chapter 5. Preclinical CRO: End-Use Estimates & Trend Analysis
5.1. Preclinical CRO Market Share, 2016 & 2025
5.2. Market Size, Estimates & Forecasts and Trend Analyses, 2014 to 2025 for the following end users:
5.2.1. Biopharmaceutical companies
5.2.1.1. Biopharmaceutical companies market estimates and forecasts, 2014 to 2025
5.2.2. Government and academic institutes
5.2.2.1. Government and academic institutes market estimates and forecasts, 2014 to 2025
5.2.3. Medical device companies
5.2.3.1. Medical device companies market estimates and forecasts, 2014 to 2025
Chapter 6. Preclinical CRO: Regional Estimates & Trend Analysis
6.1. Preclinical CRO Regional Movement Analysis & Market Share, 2016 & 2025
6.2. North America
6.2.1. U.S.
6.2.1.1. U.S. revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.2.1.2. U.S. revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
6.2.2. Canada
6.2.2.1. Canada revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.2.2.2. Canada revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
6.3. Europe
6.3.1. UK
6.3.1.1. UK revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.3.1.2. UK revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
6.3.2. Germany
6.3.2.1. Germany revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.3.2.2. Germany revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
6.4. Asia Pacific
6.4.1. Japan
6.4.1.1. Japan revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.4.1.2. Japan revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
6.4.2. China
6.4.2.1. China revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.4.2.2. China revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
6.5. Latin America
6.5.1. Brazil
6.5.1.1. Brazil revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.5.1.2. Brazil revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
6.5.2. Mexico
6.5.2.1. Mexico revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.5.2.2. Mexico revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
6.6. MEA
6.6.1. South Africa
6.6.1.1. South Africa revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.6.1.2. South Africa revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
6.6.2. Saudi Arabia
6.6.2.1. Saudi Arabia revenue estimates and forecasts by, service, 2014 – 2025 (USD Million)
6.6.2.2. Saudi Arabia revenue estimates and forecasts by, end use, 2014 – 2025 (USD Million)
Chapter 7. Competitive Landscape
7.1. Strategy Framework
7.2. Company Profiles
7.2.1. Envigo Corporation.
7.2.1.1. Company Overview
7.2.1.2. Financial Performance
7.2.1.3. Service Benchmarking
7.2.1.4. Strategic Initiatives
7.2.2. MPI research
7.2.2.1. Company Overview
7.2.2.2. Financial Performance
7.2.2.3. Service Benchmarking
7.2.2.4. Strategic Initiatives
7.2.3. Eurofins Scientific
7.2.3.1. Company Overview
7.2.3.2. Financial Performance
7.2.3.3. Service Benchmarking
7.2.3.4. Strategic Initiatives
7.2.4. PRA Health Sciences, Inc
7.2.4.1. Company Overview
7.2.4.2. Financial Performance
7.2.4.3. Service Benchmarking
7.2.4.4. Strategic Initiatives
7.2.5. Wuxi AppTec
7.2.5.1. Company Overview
7.2.5.2. Financial Performance
7.2.5.3. Service Benchmarking
7.2.5.4. Strategic Initiatives
7.2.6. Medpace, Inc.
7.2.6.1. Company Overview
7.2.6.2. Financial Performance
7.2.6.3. Service Benchmarking
7.2.6.4. Strategic Initiatives
7.2.7. Pharmaceutical Product Development (PPD), LLC
7.2.7.1. Company Overview
7.2.7.2. Financial Performance
7.2.7.3. Service Benchmarking
7.2.7.4. Strategic Initiatives
7.2.8. PARAXEL International Corporation
7.2.8.1. Company Overview
7.2.8.2. Financial Performance
7.2.8.3. Service Benchmarking
7.2.8.4. Strategic Initiatives
7.2.9. ICON Plc.
7.2.9.1. Company Overview
7.2.9.2. Financial Performance
7.2.9.3. Service Benchmarking
7.2.9.4. Strategic Initiatives
7.2.10. Laboratory Corporation of America, Inc.
7.2.10.1. Company Overview
7.2.10.2. Financial Performance
7.2.10.3. Service Benchmarking
7.2.10.4. Strategic Initiatives

List of Tables

Table 1. Country share estimation
Table 2. List of market players
Table 3. North America preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 4. North America preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 5. U.S. preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 6. U.S. preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 7. Canada preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 8. Canada preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 9. Europe preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 10. Europe preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 11. UK preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 12. UK preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 13. Germany preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 14. Germany preclinical CRO market, by end-use, 2014 - 2025 (USD Million))
Table 15. Asia Pacific preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 16. Asia Pacific preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 17. Japan preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 18. Japan preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 19. China preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 20. China preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 21. Latin America preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 22. Latin America preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 23. Brazil preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 24. Brazil preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 25. Mexico preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 26. Mexico preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 27. MEA preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 28. MEA preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
Table 29. South Africa preclinical CRO market, by service, 2014 - 2025 (USD Million)
Table 30. South Africa preclinical CRO market, by end-use, 2014 - 2025 (USD Million)




List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary (Figures in USD Million, 2016)
FIG. 8 Market trends & outlook
FIG. 9 Preclinical CRO market: Market Segmentation
FIG. 10 Preclinical CRO market revenue, (USD Million), 2014-2025
FIG. 11 Market driver relevance analysis (Current & future impact)
FIG. 12 Market restraint relevance analysis (Current & future impact)
FIG. 13 Key Opportunities Prioritized
FIG. 14 Preclinical CRO Porter’s analysis
FIG. 15 Preclinical CRO PESTEL analysis
FIG. 16 Preclinical CRO market service type outlook key takeaways
FIG. 17 Preclinical CRO market: Service Type movement analysis
FIG. 18 Bioanalysis and DMPK Studies, 2014 - 2025 (USD Million)
FIG. 19 Toxicology testing market, 2014 - 2025 (USD Million)
FIG. 20 Other preclinical services market, 2014 - 2025 (USD Million)
FIG. 21 Preclinical CRO market end use outlook key takeaways
FIG. 22 Preclinical CRO market: End Use Type movement analysis
FIG. 23 Biopharmaceutical companies market, 2014 - 2025 (USD Million)
FIG. 24 Government and academic institutes market, 2014 - 2025 (USD Million)
FIG. 25 Medical device companies market, 2014 - 2025 (USD Million)
FIG. 26 Regional market place: Key takeaways
FIG. 27 Regional outlook, 2016 & 2025
FIG. 28 North America preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 29 U.S. preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 30 Canada preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 31 Europe preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 32 UK preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 33 Germany preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 34 Asia Pacific preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 35 Japan preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 36 China Preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 37 Latin America Preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 38 Brazil Preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 39 Mexico preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 40 MEA preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 41 South Africa preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 42 Saudi Arabia Preclinical CRO market, 2014 - 2025 (USD Million)
FIG. 43 Strategy framework

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 前臨床CROの世界市場2014-2025:サービスタイプ別(生物分析・DMPK試験、毒性試験、その他の前臨床サービス)、最終用途別(Preclinical CRO Market Analysis By Service Type (Bioanalysis & DMPK Studies, Toxicology Testing, Other Preclinical Services), By End-use, And Segment Forecasts, 2014 - 2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆